ribociclib
Novartis’ new drug muscles in on Pfizer’s territory
October 10, 2016Sales and Marketing Eli Lilly, Novartis, Pfizer, ibrance, ribociclib
A drug developed by Novartis, ribociclib, when combined with an older drug, letrozole, has been shown to reduce risk of progression …
Breakthrough therapy designation for Novartis in advanced breast cancer treatment
August 3, 2016Research and Development, Sales and Marketing Breakthrough Therapy Designation, FDA, LEE011, Novartis, ribociclib
Novartis has announced that the US Food and Drug Administration (FDA) has granted a breakthrough therapy designation to LEE011 (ribociclib) …
Breast cancer trial stopped after meeting primary endpoint early
May 18, 2016Research and Development LEE011, Novartis, breast cancer, progression free survival, ribociclib
A Phase III trial evaluating LEE011 (ribociclib), developed by Novartis, has been stopped early after a recommendation from an independent …
Latest content
Global coalition calls for stronger government action on COPD
September 18, 2026
Global health researchers call for more equitable partnerships
September 17, 2026
Liverpool launches £20m lab for infectious disease drug discovery
September 16, 2026
Circle Health Group expands into UK laboratory operations
September 15, 2026
